Focus: Tenaya Therapeutics is a public biotech company focused on cardiovascular and metabolic disease therapeutics, operating as a clinical-stage developer with no approved products on the market.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Tenaya Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tenaya Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tenaya Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow Seeking Alpha
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 The Manila Times
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics to Announce New Interim Data from GlobeNewswire
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 Quiver Quantitative
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo